[go: up one dir, main page]

AR055953A1 - Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas - Google Patents

Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas

Info

Publication number
AR055953A1
AR055953A1 ARP060101986A ARP060101986A AR055953A1 AR 055953 A1 AR055953 A1 AR 055953A1 AR P060101986 A ARP060101986 A AR P060101986A AR P060101986 A ARP060101986 A AR P060101986A AR 055953 A1 AR055953 A1 AR 055953A1
Authority
AR
Argentina
Prior art keywords
hydroxamic acid
procedures
production
same
acid formulations
Prior art date
Application number
ARP060101986A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055953(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR055953A1 publication Critical patent/AR055953A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composicion farmacéutica o una composicion cristalina con un perfil de disolucion específico, que comprende ácido hidroxámico suberoilanilida o una sal farmacéuticamente aceptable o hidrato del mismo como ingrediente activo, procedimiento para producir dicha composicion cristalina o composicion farmacéutica y composiciones con una distribucion de tamano de partícula específica.
ARP060101986A 2005-05-20 2006-05-17 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas AR055953A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
AR055953A1 true AR055953A1 (es) 2007-09-12

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101986A AR055953A1 (es) 2005-05-20 2006-05-17 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas

Country Status (20)

Country Link
US (4) US8093295B2 (es)
EP (2) EP1853245A2 (es)
JP (2) JP5264174B2 (es)
KR (2) KR100884500B1 (es)
AR (1) AR055953A1 (es)
AU (3) AU2006249440C1 (es)
BR (1) BRPI0605893A (es)
CA (1) CA2580367C (es)
CR (1) CR8912A (es)
DO (1) DOP2006000113A (es)
EC (1) ECSP077263A (es)
IL (1) IL181070A0 (es)
MA (1) MA28804B1 (es)
MX (1) MX2007002047A (es)
MY (1) MY144613A (es)
NI (1) NI200700031A (es)
NZ (2) NZ553204A (es)
PE (1) PE20061390A1 (es)
TW (2) TWI365068B (es)
WO (2) WO2006127321A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009305214B2 (en) 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
EP2362870A2 (en) * 2008-11-26 2011-09-07 Generics [UK] Limited Novel processes and pure polymorphs
CA2744448A1 (en) * 2008-11-26 2010-06-03 Vinayak Gore Polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
PL348648A1 (en) 1998-10-13 2002-06-03 Fujisawa Pharmaceutical Co Cyclic tetrapeptide compound and use thereof
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
EA007649B1 (ru) 1999-09-08 2006-12-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение
PT1233958E (pt) 1999-11-23 2011-09-20 Methylgene Inc Inibidores de histona desacetilase
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2450129A1 (en) * 2001-06-14 2002-12-27 Donald G. Jackson Novel human histone deacetylases
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
CA2476434A1 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
RU2394022C2 (ru) * 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1613592A4 (en) * 2003-04-01 2008-03-12 Sloan Kettering Inst Cancer HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
PL379887A1 (pl) 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2006279400A1 (en) 2005-08-18 2007-02-22 Merck & Co. Inc. Combination methods of SAHA and Targretin for treating cancer
CN101300015A (zh) * 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
AU2006311829B8 (en) 2005-11-04 2013-02-21 Merck Sharp & Dohme Corp. Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
WO2007056232A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer

Also Published As

Publication number Publication date
NZ553204A (en) 2011-09-30
TW200727892A (en) 2007-08-01
TWI415603B (zh) 2013-11-21
JP2008519081A (ja) 2008-06-05
AU2009201652B2 (en) 2011-10-06
US8288440B2 (en) 2012-10-16
NI200700031A (es) 2008-03-03
KR20080113135A (ko) 2008-12-26
JP2011251985A (ja) 2011-12-15
JP5308486B2 (ja) 2013-10-09
CR8912A (es) 2008-02-21
US8093295B2 (en) 2012-01-10
WO2006127321A3 (en) 2007-03-22
AU2006249440B2 (en) 2009-03-12
EP2292221A3 (en) 2011-08-10
KR100993135B1 (ko) 2010-11-10
EP1853245A2 (en) 2007-11-14
AU2006249440C1 (en) 2009-08-13
KR20070062505A (ko) 2007-06-15
EP2292221A2 (en) 2011-03-09
AU2010201359A1 (en) 2010-04-29
AU2009201652A1 (en) 2009-05-21
CA2580367A1 (en) 2006-11-30
TWI365068B (en) 2012-06-01
WO2006127321A2 (en) 2006-11-30
MA28804B1 (fr) 2007-08-01
TW201034660A (en) 2010-10-01
US20100113829A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
BRPI0605893A (pt) 2007-12-18
WO2006127319A3 (en) 2007-03-29
US8450372B2 (en) 2013-05-28
MY144613A (en) 2011-10-04
AU2006249440A1 (en) 2006-11-30
US20100112046A1 (en) 2010-05-06
US20100119596A1 (en) 2010-05-13
NZ594669A (en) 2013-02-22
CA2580367C (en) 2012-08-21
US20080132575A1 (en) 2008-06-05
DOP2006000113A (es) 2006-10-31
KR100884500B1 (ko) 2009-02-20
IL181070A0 (en) 2007-07-04
ECSP077263A (es) 2007-04-26
JP5264174B2 (ja) 2013-08-14
AU2009201650B2 (en) 2011-09-15
WO2006127319A2 (en) 2006-11-30
PE20061390A1 (es) 2007-01-15
MX2007002047A (es) 2007-04-12

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
BR112014024833A8 (pt) Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia.
BR112016010403A2 (pt) Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
UY32599A (es) Formulación oral sólida de abt-263
DOP2006000170A (es) Nuevos derivados de espirocromanona
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
IN2014DN09352A (es)
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX394588B (es) Composición farmacéutica.
IN2014DN09347A (es)
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
RU2014129620A (ru) Композиции, содержащие аморфный эмодепсид
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Legal Events

Date Code Title Description
FC Refusal